Scientific article

PET radiotracers for molecular imaging in dementia

Published inCurrent radiopharmaceuticals, vol. 6, no. 4, p. 215-230
Publication date2013

Molecular imaging with various biomarkers plays a significant role in the diagnostic assessment of patients with dementing disorders, by detecting functional and pathophysiologic changes in the brain. PET imaging, in particular, allows the measurements of different molecular targets, such as functional markers of neurodegeneration (glucose metabolism), markers for pathological aggregates (such as amyloid, tau and synuclein aggregates) and neuroinflammation, and also markers of several neurotransmission systems. In the current view, neurodegenerative diseases are associated with the development of pathologic changes that play a different role in disease onset and evolution, often starting long before the onset of clinically detectable impairment. Molecular imaging represents thus a unique tool to collect relevant information contributing to accurate diagnosis, treatment and response monitoring. In this article, we review the current literature focusing on the PET radiotracers used for molecular imaging in dementia.

Citation (ISO format)
BASKIN, Aylin et al. PET radiotracers for molecular imaging in dementia. In: Current radiopharmaceuticals, 2013, vol. 6, n° 4, p. 215–230. doi: 10.2174/1874471006666131126223411
ISSN of the journal1874-4710

Technical informations

Creation09/16/2014 1:07:00 PM
First validation09/16/2014 1:07:00 PM
Update time03/14/2023 10:14:12 PM
Status update03/14/2023 10:14:12 PM
Last indexation05/02/2024 3:43:18 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack